Personalized Medical Care & Dedicated International Patient Concierge
Press Release
Skin-Beauty Academic Event Draws Spotlight to Both 'Re2O' and 'LuSkin X'
Re2O skin booster and AI device LuSkin X drew strong interest at a 2026 aesthetics conference, showing rising demand and market growth potential.
Schedule a ConsultationSkin-Beauty Academic Event Draws Spotlight to Both 'Re2O' and 'LuSkin X'
![]()
**
Steady stream of medical professionals visit society booth… "Simultaneously expanding customer base and capturing new demand"
**
The skin booster 'Re2O' and the AI-powered skin diagnostic device 'LuSkin X' drew strong interest at a recent academic conference, demonstrating both product competitiveness and market expansion potential.
According to industry sources on the 30th, L&C BIO's booth at the 2026 Botox, Filler, and Thread Lifting (BFT) Society conference, held at the Planty Room of Seoul St. Mary's Hospital, saw a steady stream of visits from medical professionals, including plastic surgery specialists.
The BFT Society conference is an academic event centered on plastic surgery and dermatology specialists, where the latest treatment trends and clinical experience are shared. Interest in skin boosters and regenerative medicine-based treatments continues to grow.
With a program built around real clinical application cases and hands-on treatment expertise, the event was recognized as an important forum for verifying product effectiveness and differentiation.
The response to Re2O on-site was enthusiastic. Medical professionals rated treatment outcomes and patient satisfaction highly, and noted strong foreign patient inflow and repeat visit rates as key strengths.
In particular, high satisfaction among treated patients was highlighted as driving a high rate of word-of-mouth referrals without the need for separate advertising, reflecting a growth structure built on organic patient acquisition.
Interest in expanding the product lineup was also notable. Inquiries increased significantly not only for the existing Re2O but also for 'Re2O Fine.' Detailed consultations followed regarding its points of differentiation from Re2O, treatment methods, pricing, and supply terms.
Lulu Lab's AI-based skin diagnostic device, LuSkin X, also drew significant attention. Interest went beyond casual curiosity, with consultations exploring actual adoption and requests for hospital visits, showing that on-site engagement was translating into real business opportunities.
Industry observers are paying close attention to the potential for a combined 'diagnosis-treatment integrated platform' strategy uniting Re2O and LuSkin X to serve as a key growth driver going forward.
Lecture sessions also attracted considerable interest. Dr. Sungtaek Hong, Director of Merry Plastic Surgery, delivered a well-received skin booster session covering ECM booster and skin booster market trends, product strengths, clinical application cases, and treatment expertise.
In particular, overall understanding of and interest in ECM boosters increased substantially, with sample requests and new consultation inquiries rising after the lecture — translating into tangible demand growth.
An industry official noted, "Through this conference, Re2O confirmed both an expanded existing user base and an influx of new customers, while Re2O Fine demonstrated its potential as a next-generation growth product."
The official added, "As LuSkin X has also generated responses that could lead to actual adoption, the integrated platform strategy combining products and devices is expected to accelerate further going forward."